Food for thought … on in silico methods in toxicology
Abstract
this series of articles has already addressed in vitro and in vivo tools (Hartung, 2007; Hartung, 2008b). With this contribution addressing computational toxicology we now try to complete considerations on the main methodological approaches in toxicology. However, we do still plan to address specific aspects, such as endpoints (omics, image technologies), high-throughput testing or physiology-based pharmaco-(toxico-)kinetic modelling (PBPK), in later issues. All of these aspects have major in silico components, which already shows how difficult it is to discuss in silico methods on their own. Indeed, their integration and interplay with in vivo and in vitro approaches is critical, at least in the way their development often depends critically on the input of either in vitro or in vivo data. this is a major difference to experimental approaches. An important consideration will thus be whether in silico methods are limited by the limitations of their input and whether we have any hope of overcoming their weaknesses or can only approximate them... there are some excellent introductions to and reviews of computational toxicology (Durham and Pearl, 2001; van de Waterbeemd, 2002; Greene, 2002; Veith, 2004, Helma, 2005; Simon-Hettich et al., 2006; Kavlock et al., 2008; Merlot, 2008; Nigsch et al., 2009; Greene and Naven, 2009). In addition, the ex-eCB website (http://ecb.jrc.ec.europa.eu/qsar/), hosted by Andrew Worth and his team (chronically understaffed given the high…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.